Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States

Li, Rui; Liu, Hanting; Fairley, Christopher K; Zou, Zhuoru; Xie, Li; Li, Xinghui; Shen, Mingwang; Li, Yan; Zhang, Lei

doi:10.1016/j.ijid.2022.03.029

Cited by 45 publications

(67 citation statements)

References 37 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quite similar to prior models [15-17], the results were most sensitive to inputs related to burden of disease and clinical effectiveness of the vaccine. Scenario analyses exploring parameter uncertainty showed that the base case results were robust.…”

Section: Discussionmentioning

confidence: 70%

“…The vast majority of the inputs used were COVID-19 specific, however, in the absence of robust COVID-19 specific disutility weights, we used proxies from other infectious diseases such as Clostridium difficile infection and influenza, which have been used in previously published COVID-19 studies [15, 17, 51]. While this may increase uncertainty in the results, sensitivity analysis demonstrated that utilities had limited impact on the overall results.…”

Section: Discussionmentioning

confidence: 99%

“…Quality-adjusted life years (QALYs) were estimated by applying utility decrements to the short and long-term symptomatic outcomes, and subtracting them from the general population age-dependent utility norms (Table S14). In the absence of robust COVID-19 specific disutility weights, we used proxies from other infectious diseases such as Clostridium difficile infection and influenza, which have been used in previously published COVID-19 studies [15, 17, 51]. Long-term QALY loss associated with early death was included on a lifetime horizon and discounted at 3% annually.…”

Section: Methodsmentioning

confidence: 99%

“…Leveraging national surveillance data, studies quantified the population-level impact of COVID-19 vaccination in the US and showed that vaccines are clinically effective in reducing symptomatic cases, deaths, and hospitalizations [10][11][12][13]. However, only a few studies assessed the economic impact of COVID-19 vaccination in the US [14][15][16][17][18][19]. Kohli et al, [15] and Padula et al, [16], published in the early stages of the pandemic, assessed the cost-effectiveness of a hypothetical COVID-19 vaccine meeting the WHO and Food and Drug Administration (FDA) target product profiles.…”

Section: The Coronavirus Disease 2019 (Covid-19) Pandemic Has Claimed...mentioning

confidence: 99%

“…Kohli et al, [15] and Padula et al, [16], published in the early stages of the pandemic, assessed the cost-effectiveness of a hypothetical COVID-19 vaccine meeting the WHO and Food and Drug Administration (FDA) target product profiles. Li et al, [17] estimated the cost-effectiveness of a booster strategy of BNT162b2 in individuals aged ≥65 years. Although the three studies demonstrated cost-effectiveness versus no vaccination, they focused on the healthcare system perspective, which may arguably underestimate the full value of vaccination.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Public Health Impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Fusco

Marczell²,

Deger

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: As the body of evidence on COVID-19 and post-vaccination outcomes continues to expand, this analysis sought to evaluate the public health impact of the Pfizer-BioNTech COVID-19 Vaccine, BNT162b2, during the first year of its rollout in the US. Methods: A combined Markov decision tree model compared clinical and economic outcomes of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) versus no vaccination in individuals aged ≥12 years. Age-stratified epidemiological, clinical, economic, and humanistic parameters were derived from existing data and published literature. Scenario analysis explored the impact of using lower and upper bounds of parameters on the results. The health benefits were estimated as the number of COVID-19 symptomatic cases, hospitalizations and deaths averted, and Quality Adjusted Life Years (QALYs) saved. The economic benefits were estimated as the amount of healthcare and societal cost savings associated with the vaccine-preventable health outcomes. Results: It was estimated that, in 2021, the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) contributed to averting almost 9 million symptomatic cases, close to 700,000 hospitalizations, and over 110,000 deaths, resulting in an estimated $30.4 billion direct healthcare cost savings, $43.7 billion indirect cost savings related to productivity loss, as well as discounted gains of 1.1 million QALYs. Scenario analyses showed that these results were robust; the use of alternative plausible ranges of parameters did not change the interpretation of the findings. Conclusions: The Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) contributed to generate substantial public health impact and vaccine-preventable cost savings in the first year of its rollout in the US. The vaccine was estimated to prevent millions of COVID-19 symptomatic cases and thousands of hospitalizations and deaths, and these averted outcomes translated into cost-savings in the billions of US dollars and thousands of QALYs saved. As only direct impacts of vaccination were considered, these estimates may be conservative.

show abstract

Section: Discussionmentioning

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: The Coronavirus Disease 2019 (Covid-19) Pandemic Has Claimed...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Public Health Impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Fusco

Marczell²,

Deger

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

Analyzing the emerging patterns of SARS‐CoV‐2 Omicron subvariants for the development of next‐gen vaccine: An observational study

Mohapatra,

Mishra,

Kandi

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background and AimUnderstanding the prevalence and impact of SARS‐CoV‐2 variants has assumed paramount importance. This study statistically analyzed to effectively track the emergence and spread of the variants and highlights the importance of such investigations in developing potential next‐gen vaccine to combat the continuously emerging Omicron subvariants.MethodsTransmission fitness advantage and effective reproductive number (Re) of epidemiologically relevant SARS‐CoV‐2 sublineages through time during the study period based on the GISAID data were estimated.ResultsThe analyses covered the period from January to June 2023 around an array of sequenced samples. The dominance of the XBB variant strain, accounting for approximately 57.63% of the cases, was identified during the timeframe. XBB.1.5 exhibited 37.95% prevalence rate from March to June 2023. Multiple variants showed considerable global influence throughout the study, as sporadically documented. Notably, the XBB variant demonstrated an estimated relative 28% weekly growth advantage compared with others. Numerous variants were resistant to the over‐the‐counter vaccines and breakthrough infections were reported. Similarly, the efficacy of mAB‐based therapy appeared limited. However, it's important to underscore the perceived benefits of these preventive and therapeutic measures were restricted to specific variants.ConclusionGiven the observed trends, a comprehensive next‐gen vaccine coupled with an advanced vaccination strategy could be a potential panacea in the fight against the pandemic. The findings suggest that targeted vaccine development could be an effective strategy to prevent infections. The study also highlights the need of global collaborations to rapidly develop and distribute the vaccines to ensure global human health.

show abstract

Harmalogical Pharmacology and the Covid-19 Vaccine

Briggs,

Telford,

Lloyd

et al. 2023

The New Futures of Exclusion

View full text Add to dashboard Cite

Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States

Cited by 45 publications

References 37 publications

Public Health Impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Public Health Impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Analyzing the emerging patterns of SARS‐CoV‐2 Omicron subvariants for the development of next‐gen vaccine: An observational study

Harmalogical Pharmacology and the Covid-19 Vaccine

Contact Info

Product

Resources

About